论文部分内容阅读
目的:探讨乌苯美司胶囊联合SOX化疗对晚期胃癌患者的临床疗效及安全性。方法:选择2013年9月至2015年9月我院接诊的90例晚期胃癌患者,通过随机数表法分为观察组(n=45)和对照组(n=45)。对照组给予SOX化疗方案,观察组在此基础上联合乌苯美司胶囊。比较两组治疗前后CD_4~+、CD_8~+、CD_4~+/CD_8~+、血清基质金属蛋白酶(MMP)-2、MMP-9水平、临床疗效、不良反应发生情况以及6个月、12个月生存率。结果:治疗后,观察组CD_4+、CD_4~+/CD_8~+显著高于对照组(P<0.05),血清MMP2、MMP-9水平明显低于对照组(P<0.05);临床疗效总有效率高于对照组[68.89%(31/45)vs48.89%(22/45)](P<0.05),血小板下降、白细胞下降、恶心呕吐、肝功异常的发生率均显著低于对照组(P<0.05)。观察组在6个月、12个月时生存率均高于对照组[93.33%(42/45)vs77.78%(35/45),82.22%(37/45)vs57.78%(26/45)](P<0.05)。结论:与单用SOX方案相比,乌苯美司胶囊联合SOX化疗方案治疗晚期胃癌患者的效果显著,可有效改善免疫功能,提高远期生存率,且安全性更高。
Objective: To investigate the clinical efficacy and safety of ubenimex capsules combined with SOX chemotherapy in patients with advanced gastric cancer. Methods: Ninety patients with advanced gastric cancer admitted to our hospital from September 2013 to September 2015 were divided into observation group (n = 45) and control group (n = 45) by random number table. Control group was given SOX chemotherapy, the observation group on this basis combined with ubenimex capsules. The levels of CD_4 ~ +, CD_8 ~ +, CD_4 ~ + / CD_8 ~ +, serum MMP-2 and MMP-9 levels in the two groups before and after treatment were compared, and the clinical efficacy, adverse reactions, Monthly survival rate. Results: After treatment, the levels of CD_4 + and CD_4 + / CD_8 + in the observation group were significantly higher than those in the control group (P <0.05), and the levels of serum MMP2 and MMP-9 in the observation group were significantly lower than those in the control group (P <0.05). The incidence of thrombocytopenia, leukopenia, nausea and vomiting, abnormal liver function were significantly lower than those in the control group (68.89% vs 31/45 vs 48.89% (22/45) P <0.05). The survival rates of the observation group at 6 months and 12 months were higher than that of the control group [93.33% (42/45) vs 77.78% (35/45), 82.22% (37/45 vs 57.78%, 26 / 45)] (P <0.05). Conclusion: Compared with the single SOX regimen, ubenimex capsule combined with SOX chemotherapy is effective in treating patients with advanced gastric cancer, which can effectively improve immune function, improve long-term survival rate and have higher safety.